Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL946511 | 0.98 | HTR6 (0.39) | HTR6RAD52 | |
| SCHEMBL1647530 | 0.92 | HTR6 (0.36) | HTR6SMN1; SMN2 | |
| SCHEMBL6274716 | 0.86 | HTR6 (0.37) | HTR6 | |
| SCHEMBL286072 | 0.83 | CYP2D6 (0.32) | HTR6CHRM5 | |
| SCHEMBL10891279 | 0.83 | CYP2D6 (0.32) | HTR6CHRM5 | |
| SCHEMBL2229452 | 0.83 | CYP2D6 (0.32) | HTR6CHRM5 | |
| SCHEMBL2569149 | 0.83 | CYP2D6 (0.32) | HTR6CHRM5 | |
| SCHEMBL4712511 | 0.83 | CYP2D6 (0.32) | HTR6CHRM5 | |
| SCHEMBL3658217 | 0.83 | CYP2D6 (0.32) | HTR6CHRM5 | |
| SCHEMBL6050828 | 0.83 | CYP2D6 (0.32) | HTR6CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209514-A1 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists | TAJIMI MASAOMI | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209514-A1 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists | OPRL1, TRPV1, LTB4R | HTR6 554/4885RAD52 2821/4885USP2 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.